Hazte socio de la SAMFyC

Última publicación SAMFyC: Actualización en MF y APS

 

AULA VIRTUAL SAMFyC

Aula de formación virtual de SAMFyC

SAMFyC CONGRESOS

Historico de Comunicaciones
presentadas a los Congresos
Andaluces de MFyC (SAMFyC), desde 2008.


* * * * * * * * * * * * * * * * * * * * * * * * *

Información Socios

Ofertas de Trabajo
Ofertas de Trabajo SOCIOS SAMFYC

¡Actualiza tus datos!
Actualiza tus datos

 

Buscador de Contenidos

Sociedades Federadas

Medicina Familiar y Comunitaria

Sociedades Científicas de Medicina Familiar y Comunitaria

Enlaces de Interés

Consulte Nuestros Enlaces.
Enlaces de Interés

Acceso Socios



 

Buscador de publicaciones externas y alertas bibliográficas

Febrero 2014 PDF Imprimir E-mail
Viernes, 07 de Marzo de 2014 00:00

<< Volver

SELECCIÓN DE REFERENCIAS BIBLIOGRÁFICAS DE LO PUBLICADO EN RELACIÓN CON ATENCIÓN PRIMARIA
Selección realizada por Antonio Manteca González
 
 
Sklar DP. How do we think? Can we learn to think better? Acad Med. 2014; 89:191-193 [AO,I]
¿CÓMO PENSAMOS? ¿PODEMOS APRENDER A PENSAR MEJOR?
 
Croskerry P, Petrie DA, Reilly JB, Tait G. Deciding about fast and slow decisions. Acad Med. 2014; 89:197-200 [AO,I]
DECIDIR SOBRE LAS DECISIONES RÁPIDAS Y LENTAS
 
Bynum W. Why physicians need to be more than automated medical kiosks. Acad Med. 2014; 89:212-214 [AO,I]
POR QUÉ LOS MÉDICOS NECESITAN SER MÁS QUE PUNTOS DE INFORMACIÓN MÉDICA AUTOMATIZADOS
 
 
O'Donoghue C, Eklund M, Ozanne EM, Esserman LJ. Aggregate cost of mammography screening in the United States: comparison of current practice and advocated guidelines. Ann Intern Med. 2014; 160:145-153 [CE,I]
COSTE AGREGADO DEL CRIBAJE MEDIANTE MAMOGRAFÍA EN LOS EE UU: COMPARACIÓN ENTRE LA PRÁCTICA ACTUAL Y LAS PAUTAS RECOMENDADAS
 
Lee JK. Liles EG, Bent S, Levin TR; Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014; 160:171-181 [M,II]
EXACTITUD DE LAS PRUEBAS INMUNOQUÍMICAS FECALES PARA EL CÁNCER COLORRECTAL: REVISIÓN SISTEMÁTICA Y METAANÁLISIS
 
Gillick MR. When frail elderly adults get sick: alternatives to hospitalization . Ann Intern Med. 2014; 160:201-202 [AO,I]
CUANDO LOS ANCIANOS FRÁGILES SE PONEN ENFERMOS: ALTERNATIVAS A LA HOSPITALIZACIÓN
 
Bridges CB, Coyne-Beasley T; on behalf of the Advisory Committee on Immunization Practices. Recommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2014* Ann Intern Med. 2014; 160:190-197 [M,II]
CALENDARIO DE VACUNAS RECOMENDADAS PARA ADULTOS DE 19 AÑOS O MÁS: ESTADOS UNIDOS, 2014
 
Kazi DS, Garber AM, Shah RU, Dudley RA, Mell MW, Rhee C, et al. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Ann Intern Med. 2014; 160:221-232 [CE,I]
RENTABILIDAD DE LAS TERAPIAS ANTIPLAQUETARIAS DUALES Y GUIADAS POR GENOTIPO EN EL SÍNDROME CORONARIO AGUDO
 
Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014; 160:233-242 [EC,I]
TRATAMIENTO DEL SÍNDROME DE SJÖGREN PRIMARIO CON RITUXIMAB: ENSAYO ALEATORIZADO
 
Moyer VA; on behalf of the U.S. Preventive Services Task Force*. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 160:271-281 [M,II]
VALORACIÓN DEL RIESGO, CONSEJO GENÉTICO Y PRUEBAS GENÉTICAS EN EL CÁNCER RELACIONADO CON BRCA EN MUJERES: DECLARACIÓN DE RECOMENDACIÓN DEL USPSTF
 
Wong JB. Evidence-based medicine, pharmacogenetics, and antiplatelet therapy decision making for acute coronary syndrome. Ann Intern Med. 2014; 160:284-285 [AO,I]
MEDICINA BASADA EN LA EVIDENCIA, FARMACOGENÉTICA Y TOMA DE DECISIONES SOBRE TERAPIA ANTIPLAQUETARIA EN EL SÍNDROME CORONARIO AGUDO
 
 
Parente I, Abal J, Blanco N, Alves MT, Dacal R, Gómez H, et al. Características clínicas y supervivencia de los pacientes nunca fumadores con cáncer de pulmón. Arch Bronconeumol. 2014; 50:62-66 [S,I]
CARACTERÍSTICAS CLÍNICAS Y SUPERVIVENCIA DE LOS PACIENTES NUNCA FUMADORES CON CÁNCER DE PULMÓN
 
 
Lobos JM, Polo J, Vargas D. El médico de familia ante las barreras en la prescripción de los nuevos anticoagulantes orales: heterogeneidad, inequidad y confusión. Posicionamiento de las Sociedades Científicas de Atención Primaria en España.  Aten Primaria. 2014; 46:1-3 [M,II]
EL MÉDICO DE FAMILIA ANTE LAS BARRERAS EN LA PRESCRIPCIÓN DE LOS NUEVOS ANTICOAGULANTES ORALES: HETEROGENEIDAD, INEQUIDAD Y CONFUSIÓN. POSICIONAMIENTO DE LAS SOCIEDADES CIENTÍFICAS DE ATENCIÓN PRIMARIA EN ESPAÑA
 
Leon-Sanromà M, Mínguez J, Cerecedo MJ, Téllez J. ¿Nos pasamos al DSM-5? Un debate con implicaciones clínicas, sociales y económicas. Aten Primaria. 2014; 46:4-5 [AO,I]
¿NOS PASAMOS AL DSM-5? UN DEBATE CON IMPLICACIONES CLÍNICAS, SOCIALES Y ECONÓMICAS
 
Catalán-Ramos A, Verdú JM, Grau M, Iglesias-Rodal M, Del Val JL, Consola A, Comin E; @GPC-ICS Group. Prevalencia y control de factores de riesgo cardiovascular en la población general: ¿qué nos dice la historia clínica electrónica? Aten Primaria. 2014; 46:15-24 [T,I]
PREVALENCIA Y CONTROL DE FACTORES DE RIESGO CARDIOVASCULAR EN LA POBLACIÓN GENERAL: ¿QUÉ NOS DICE LA HISTORIA CLÍNICA ELECTRÓNICA?
 
Hernández-Díaz J, Paredes-Carbonell JJ, Marín R. Cómo diseñar talleres para promover la salud en grupos comunitarios. Aten Primaria. 2014; 46:40-47 [R,I]
CÓMO DISEÑAR TALLERES PARA PROMOVER LA SALUD EN GRUPOS COMUNITARIOS
 
Ribera JA, Córdoba R, Gascó P. El cigarrillo electrónico: la utopía del cigarrillo seguro. Aten Primaria. 2014; 46:53-54 [AO,I]
EL CIGARRILLO ELECTRÓNICO: LA UTOPÍA DEL CIGARRILLO SEGURO
 
Lesende IM. Crisis económica y vulnerabilidad social en personas mayores. Aten Primaria. 2014; 46:55-57 [AO,I]
CRISIS ECONÓMICA Y VULNERABILIDAD SOCIAL EN PERSONAS MAYORES
 
Giménez-García E, Clua-Espuny JL, Bosch-Príncep R, López-Pablo C, Lechuga-Durán I, Gallofré-López M, et al. El circuito asistencial de la fibrilación auricular en pacientes ambulatorios: estudio observacional Audit fibrilación auricular en el Baix Ebre. Aten Primaria. 2014; 46:58-67 [T,I]
EL CIRCUITO ASISTENCIAL DE LA FIBRILACIÓN AURICULAR EN PACIENTES AMBULATORIOS: ESTUDIO OBSERVACIONAL AUDIT FIBRILACIÓN AURICULAR EN EL BAIX EBRE
 
Báez-Montiel BB, Gutiérrez-Islas E, Bolaños-Maldonado M, Samarín E, Turabián JL. Las odiseas de los Ulises. Estudio de los relatos de un día normal de trabajo del médico de familia en Paraguay, México, Perú y España. Aten Primaria. 2014; 46:68-76 [C,I]
LAS ODISEAS DE LOS ULISES. ESTUDIO DE LOS RELATOS DE UN DÍA NORMAL DE TRABAJO DEL MÉDICO DE FAMILIA EN PARAGUAY, MÉXICO, PERÚ Y ESPAÑA
 
Alfaro-Lara ER, Vega-Coca MD, Galván-Banqueri M, Nieto-Martín MD, Pérez-Guerrero C, Santos-Ramos B. Metodología de conciliación del tratamiento farmacológico en pacientes pluripatológicos. Aten Primaria. 2014; 46:89-99 [R,II]
METODOLOGÍA DE CONCILIACIÓN DEL TRATAMIENTO FARMACOLÓGICO EN PACIENTES PLURIPATOLÓGICOS
 
 
Sharpe M. Psychological medicine and the future of psychiatry. Br J Psychiatry. 2014; 204:91-92 [AO,I]
MEDICINA PSICOLÓGICA Y EL FUTURO DE LA PSIQUIATRÍA
 
Craddock N, Mynors-Wallis L. Psychiatric diagnosis: impersonal, imperfect and important. Br J Psychiatry. 2014; 204:93-95 [AO,I]
DIAGNÓSTICO PSIQUIÁTRICO: IMPERSONAL, IMPERFECTO E IMPORTANTE
 
Barrett J. Disorders of gender identity: what to do and who should do it? Br J Psychiatry. 2014; 204:96-97 [AO,I]
TRASTORNOS DE IDENTIDAD SEXUAL: ¿QUÉ HACER Y QUIÉN DEBERÍA HACERLO?
 
Gould RL, Coulson MC, Patel N, Highton-Williamson E, Howard RJ. Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. Br J Psychiatry. 2014; 204:98-107 [M,II]
INTERVENCIONES PARA REDUCIR EL USO DE BENZODIACEPINAS EN LAS PERSONAS MAYORES: METAANÁLISIS DE ENSAYOS CONTROLADOS ALEATORIZADOS
 
 
Cohen SP1, Mao J. Neuropathic pain: mechanisms and their clinical implications. BMJ. 2014; 348:f7656 [R,I]
DOLOR NEUROPÁTICO: MECANISMOS Y SUS IMPLICACIONES CLÍNICAS
 
Jaddoe VW, de Jonge LL, Hofman A, Franco OH, Steegers EA, Gaillard R. First trimester fetal growth restriction and cardiovascular risk factors in school age children: population based cohort study. BMJ. 2014; 348:g14 [S,I]
RESTRICCIÓN DEL CRECIMIENTO FETAL DEL PRIMER TRIMESTRE Y FACTORES DE RIESGO CARDIOVASCULAR EN NIÑOS EN EDAD ESCOLAR: ESTUDIO DE COHORTE POBLACIONAL
 
Bush A, Grigg J, Saglani S. Managing wheeze in preschool children. BMJ. 2014; 348:g15 [R,I]
MANEJAR LAS SIBILANCIAS EN LOS NIÑOS PREESCOLARES
 
Muneer A1, Kalsi J, Nazareth I, Arya M. Erectile dysfunction. BMJ. 2014; 348:g129 [R,I]
DISFUNCIÓN ERÉCTIL
 
Prochaska JJ. Quitting smoking is associated with long term improvements in mood. BMJ. 2014; 348 [AO,I]
EL ABANDONO DEL TABACO SE ASOCIA A UNA MEJORA DEL HUMOR A LARGO PLAZO
 
Aiken CE, Smith GC. Early fetal growth and risk factors for cardiovascular disease. BMJ. 2014; 348:g175 [AO,I]
CRECIMIENTO FETAL TEMPRANO Y FACTORES DE RIESGO DE ENFERMEDAD CARDIOVASCULAR
 
Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014; 348:g226 [T,II]
MASTECTOMÍA CONTRALATERAL Y SUPERVIVENCIA TRAS CÁNCER DE MAMA EN PORTADORAS DE MUTACIONES BRCA1 Y BRCA2: ANÁLISIS RETROSPECTIVO
 
O'Riordan P, Stevens PE, Lamb EJ. Estimated glomerular filtration rate. BMJ. 2014; 348:g264 [R,I]
TASA ESTIMADA DE FILTRACIÓN GLOMERULAR
 
Ebrahim S, Taylor FC, Brindle P. Statins for the primary prevention of cardiovascular disease. BMJ. 2014; 348:g280 [R,I]
ESTATINAS EN LA PREVENCIÓN PRIMARIA DE ENFERMEDAD CARDIOVASCULAR
 
Kontopantelis E, Springate D, Reeves D, Ashcroft DM, Valderas JM, Doran T. Withdrawing performance indicators: retrospective analysis of general practice performance under UK Quality and Outcomes Framework. BMJ. 2014; 348:g330 [S,II]
RETIRADA DE LOS INDICADORES DE RENDIMIENTO: ANÁLISIS RETROSPECTIVO DEL RENDIMIENTO DE LA MEDICINA GENERAL BAJO EL MARCO DE CALIDAD Y RESULTADOS DEL RU
 
Wedzicha JA, Steinbrook R, Kassirer JP. Should medical journals publish sponsored content? BMJ. 2014; 348:g352 [AO,II]
¿DEBERÍAN PUBLICAR CONTENIDO PATROCINADO LAS REVISTAS MÉDICAS?
 
Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014; 348:g366 [EC,II]
25 AÑOS DE SEGUIMIENTO DE LA INCIDENCIA DE CÁNCER DE MAMA Y SU MORTALIDAD EN EL ESTUDIO DE CRIBAJE NACIONAL CANADIENSE DE MAMA: ENSAYO ALEATORIZADO DE CRIBAJE
 
Chapman S. When will the tobacco industry apologise for its monstrous harms? BMJ. 2014; 348:g437 [AO,I]
¿CUÁNDO PEDIRÁ PERDÓN LA INDUSTRIA DEL TABACO POR SUS MONSTRUOSOS DAÑOS?
 
Ekström MP, Bornefalk-Hermansson A, Abernethy AP, Currow DC. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ. 2014; 348:g445 [S,I]
SEGURIDAD DE LAS BENZODIACEPINAS Y OPIOIDES EN LA ENFERMEDAD RESPIRATORIA GRAVE: ESTUDIO PROSPECTIVO NACIONAL
 
Zakrzewska JM1, Linskey ME. Trigeminal neuralgia. BMJ. 2014; 348:g474 [R,I]
NEURALGIA DEL TRIGÉMINO
 
Hotchkiss JW, Davies CA, Dundas R, Hawkins N, Jhund PS, Scholes S, et al. Explaining trends in Scottish coronary heart disease mortality between 2000 and 2010 using IMPACTSEC model: retrospective analysis using routine data. BMJ. 2014; 348:g1088 [T,I]
EXPLICAR LAS TENDENCIAS ESCOCESAS EN MORTALIDAD POR ENFERMEDAD CARDIACA ENTRE 2000 Y 2010 USANDO EL MODELO IMPACTSEC: ANÁLISIS RETROSPECTIVO USANDO DATOS RUTINARIOS
 
Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P. Change in mental health after smoking cessation: systematic review and meta-analysis. BMJ. 2014; 348:g1151 [M,II]
CAMBIO EN LA SALUD MENTAL TRAS DEJAR DE FUMAR: REVISIÓN SISTEMÁTICA Y METAANÁLISIS
 
Kuipers E, Yesufu-Udechuku A, Taylor C, Kendall T. Management of psychosis and schizophrenia in adults: summary of updated NICE guidance. BMJ. 2014; 348:g1173 [M,II]
MANEJO DE LA PSICOSIS Y LA ESQUIZOFRENIA EN ADULTOS: RESUMEN DE LA GUÍA NICE ACTUALIZADA
 
Pless C, Pless B. Mobile phones and driving. BMJ. 2014; 348:g1193 [AO,I]
TELÉFONOS MÓVILES Y CONDUCCIÓN
 
Godlee F. Towards the patient revolution. BMJ. 2014; 348:g1209
HACIA LA REVOLUCIÓN DEL PACIENTE
 
Rahman A1, Underwood M, Carnes D. Fibromyalgia. BMJ. 2014; 348:g1224 [R,I]
FIBROMIALGIA
 
Thombs BD, Ziegelstein RC. Does depression screening improve depression outcomes in primary care? BMJ. 2014; 348:g1253 [R,I]
¿MEJORA EL CRIBAJE DE LA DEPRESIÓN LOS RESULTADOS DE LA DEPRESIÓN EN ATENCIÓN PRIMARIA?
 
Michels KB. Contralateral mastectomy for women with hereditary breast cancer. BMJ. 2014; 348:g1379 [AO,I]
MASTECTOMÍA CONTRALATERAL EN MUJERES CON CÁNCER DE MAMA HEREDITARIO
 
Kalager M, Adami HO, Bretthauer M. Too much mammography. BMJ. 2014; 348:g1403 [AO,II]
DEMASIADAS MAMOGRAFÍAS
 
Guthrie B, Morales DR. What happens when pay for performance stops? BMJ. 2014; 348:g1413 [AO,I]
¿QUÉ PASA CUANDO CESA EL PAGO POR RENDIMIENTO?
 
Address RR. Medicine: a partnership of trust and faith. BMJ. 2014; 348:g1452 [AO,I]
MEDICINA: UNA COLABORACIÓN DE FE Y VERDAD
 
Ross JCC. Why is the incidence of pelvic inflammatory disease falling? BMJ. 2014; 348:g1538 [AO,I]
¿POR QUÉ ESTÁ DECAYENDO LA INCIDENCIA DE ENFERMEDAD PÉLVICA INFLAMATORIA?
 
Rashid MA. Consultations in primary care should be held standing up. BMJ. 2014; 348:g1558 [AO,I]
LAS CONSULTAS DE ATENCIÓN PRIMARIA SE DEBERÍAN MANTENER DE PIE
 
 
Redelmeier DA, Tien HC. Medical interventions to reduce motor vehicle collisions. CMAJ. 2014; 186:118-124 [R,I]
INTERVENCIONES MÉDICAS PARA REDUCIR LAS COLISIONES DE VEHÍCULOS DE MOTOR
 
Carson MP, Chen KK. Hypertension in a woman planning pregnancy. CMAJ. 2014; 186:129-130 [AO,I]
HIPERTENSIÓN EN MUJER QUE PLANIFICA EL EMBARAZO
 
Järvinen TL, Jokihaara J, Guy P, Alonso-Coello P, Collins GS, Michaëlsson K, et al. Conflicts at the heart of the FRAX tool. CMAJ. 2014; 186:165-167 [AO,I]
CONFLICTOS EN EL CORAZÓN DE LA HERRAMIENTA FRAX
 
Allan GM, Arroll B. Prevention and treatment of the common cold: making sense of the evidence.
CMAJ. 2014; 186:190-199 [R,I]
PREVENCIÓN Y TRATAMIENTO DEL RESFRIADO COMÚN: DAR SENTIDO A LA EVIDENCIA
 
Moayedi Y, Abdel-Qadir HM, Dorian P. Evaluation and care of a patient with new-onset atrial fibrillation. CMAJ. 2014; 186:204-205 [R,I]
EVALUACIÓN Y CUIDADOS DE UN PACIENTE CON FIBRILACIÓN AURICULAR DE NUEVA APARICIÓN
 
 
Martin SS, Michos ED. Are we moving towards concordance on the principle that lipid discordance matters? Circulation. 2014; 129:539-541 [AO,I]
¿ESTAMOS YENDO HACIA LA CONCORDANCIA RESPECTO A QUE LA DISCORDANCIA LIPÍDICA IMPORTA?
 
Stanton RC. Sodium Glucose Transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease? Circulation. 2014; 129:542-544 [AO,I]
LA INHIBICIÓN DEL TRANSPORTE DE SODIO GLUCOSA 2 (SGLT2) DISMINUYE LA HIPERFILTRACIÓN GLOMERULAR: ¿HAY UN PAPEL PARA LOS INHIBIDORES DE SGLT2 EN LA ENFERMEDAD RENAL DIABÉTICA?
 
Mora S, Buring JE, Ridker PM. Discordance of Low-Density Lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation. 2014; 129:553-561 [S,II]
DISCORDANCIA ENTRE COLESTEROL LDL CON LAS MEDICIONES ALTERNATIVAS RELACIONADAS CON LDL Y FUTUROS ACONTECIMIENTOS CORONARIOS
 
Chen H, Burnett RT, Kwong JC, Villeneuve PJ, Goldberg MS, Brook RD, et al. Spatial association between ambient fine particulate matter and incident hypertension. Circulation. 2014; 129:562-569 [S,II]
ASOCIACIÓN ESPACIAL ENTRE PARTÍCULAS FINAS AMBIENTALES E INCIDENCIA DE HIPERTENSIÓN
 
Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (Justification for the se of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation. 2014; 129:635-642 [EC,II]
CONCENTRACIONES DE LIPOPROTEÍNA (A), TRATAMIENTO CON ROSUVASTATINA Y RIESGO VASCULAR RESIDUAL: ANÁLISIS A PARTIR DEL ENSAYO JUPITER
 
Seaburg L, Hess EP, Coylewright M, Ting HH, McLeod CJ, Montori VM. Shared decision making in atrial fibrillation: where we are and where we should be going. Circulation. 2014; 129:704-710 [R,I]
TOMA DE DECISIONES COMPARTIDA EN LA FIBRILACIÓN AURICULAR: DÓNDE ESTAMOS Y HACIA DÓNDE DEBERÍAMOS ESTAR YENDO
 
Verhamme P, Bounameaux H. Direct oral anticoagulants for acute venous thromboembolism: closing the circle? Circulation. 2014; 129:725-727 [AO,I]
ANTICOAGULANTES ORALES DIRECTOS EN EL TROMBOEMBOLISMO VENOSO AGUDO: ¿CIERRE DEL CÍRCULO?
 
Li Y, Zhang X, Winkelman JW, Redline S, Hu FB, Stampfer M, et al. Association between insomnia symptoms and mortality: a prospective study of US men. Circulation. 2014; 129:737-746 [S,I]
ASOCIACIÓN ENTRE SÍNTOMAS DE INSOMNIO Y MORTALIDAD: ESTUDIO PROSPECTIVO EN HOMBRES ESTADOUNIDENSES
 
Sidloff D, Stather P, Dattani N, Bown M, Thompson J, Sayers R, et al. Aneurysm global epidemiology study: public health measures can further reduce abdominal aortic aneurysm mortality. Circulation. 2014; 129:747-753 [T,I]
ESTUDIO EPIDEMIOLÓGICO MUNDIAL DEL ANEURISMA: LAS MEDIDAS DE SALUD PÚBLICA PUEDEN REDUCIR POSTERIORMENTE LA MORTALIDAD POR ANEURISMA AÓRTICO ABDOMINAL
 
Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al; RE-COVER II Trial Investigators*. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014; 129:764-772 [EC,II]
TRATAMIENTO DEL TROMBOEMBOLISMO VENOSO AGUDO CON DABIGATRAN O WARFARINA Y ANÁLISIS COMBINADO
 
Alonso A1, Bengtson LG. A rising tide: the global epidemic of atrial fibrillation. Circulation. 2014; 129:829-830 [AO,I]
MAREA QUE SUBE: EPIDEMIA MUNDIAL DE FIBRILACIÓN AURICULAR
 
Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014; 129:837-847 [M,II]
EPIDEMIOLOGÍA MUNDIAL DE LA FIBRILACIÓN AURICULAR: EL ESTUDIOM DE CARGA MUNDIAL DE ENFERMEDAD 2010
 
Patrono C, Baigent C. Nonsteroidal anti-inflammatory drugs and the heart. Circulation. 2014; 129:907-916 [R,II]
FÁRMACOS AINE Y CORAZÓN
 
 
Phan TL, Hossain J, Lawless S, Werk LN. Quarterly visits with glycated hemoglobin monitoring: the sweet spot for glycemic control in youth with type 1 diabetes. Diabetes Care. 2014; 37:341-345 [S,II]
VISITAS TRIMESTRALES CON MONITORIZACIÓN DE HEMOGLOBINA GLUCOSILADA: EL PUNTO IDEAL PARA LOS JÓVENES CON DIABETES TIPO 1
 
R, et al. Initiation and gradual intensification of premixed insulin lispro therapy versus Basal {} mealtime insulin in patients with type 2 diabetes eating light breakfasts. Diabetes Care. 2014; 37:372-380 [EC,I]
INICIACIÓN E INTENSIFICACIÓN GRADUAL DE TRATAMIENTO CON INSULINA LISPRO PREMEZCLADA FRENTE A INSULINA BASAL MÁS INSULINA EN LAS COMIDAS EN PACIENTES CON DIABETES TIPO 2 QUE TOMAN DESAYUNOS LIGEROS
 
Pettitt DJ, Talton J, Dabelea D, Divers J, Imperatore G, Lawrence JM, et al; SEARCH for Diabetes in Youth Study Group. Prevalence of diabetes in U.S. youth in 2009: the SEARCH for Diabetes in Youth study. Diabetes Care. 2014; 37:402-408 [T,II]
PREVALENCIA DE DIABETES EN LA JUVENTUD ESTADOUNIDENSE EN 2009: EL ESTUDIO SEARCH FOR DIABETES IN YOUTH
 
Hruby A, Meigs JB, O'Donnell CJ, Jacques PF, McKeown NM. Higher magnesium intake reduces risk of impaired glucose and insulin metabolism and progression from prediabetes to diabetes in middle-aged americans. Diabetes Care. 2014; 37:419-427 [T,I]
UNA INGESTA MAYOR DE MAGNESIO REDUCE EL RIESGO DE GLUCEMIA Y METABOLISMO DE INSULINA ALTERADOS Y LA PROGRESIÓN DE PREDIABETES A DIABETES EN LOS AMERICANOS DE EDAD MEDIANA
 
Feinkohl I, Aung PP, Keller M, Robertson CM, Morling JR, McLachlan S, et al; Edinburgh Type 2 Diabetes Study (ET2DS) Investigators. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh Type 2 Diabetes study. Diabetes Care. 2014; 37:507-515 [S,I]
HIPOGLUCEMIA GRAVE Y DECLIVE COGNITIVO EN PERSONAS MAYORES CON DIABETES TIPO 2: ESTUDIO EDINBURGH TYPE 2 DIABETES
 
Stahn A, Pistrosch F, Ganz X, Teige M, Koehler C, Bornstein S, et al. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias. Diabetes Care. 2014; 37:516-520 [T,I]
RELACIÓN ENTRE EPISODIOS HIPOGLUCÉMICOS Y ARRITMIAS VENTRICULARES EN PACIENTES CON DIABETES TIPO 2 Y ENFERMEDADES CARDIOVASCULARES: HIPOGLUCEMIAS SILENTES Y ARRITMIAS SILENTES
 
McAuley PA, Artero EG, Sui X, Lavie CJ, Almeida MJ, Blair SN. Fitness, fatness, and survival in adults with prediabetes. Diabetes Care. 2014; 37:529-536 [S,I]
ESTADO DE FORMA, GORDURA Y SUPERVIVENCIA EN ADULTOS CON PREDIABETES
 
Bannister CA, Poole CD, Jenkins-Jones S, Morgan CL, Elwyn G, Spasic I, et al. External validation of the UKPDS risk engine in incident type 2 diabetes: a need for new type 2 diabetes-specific risk equations. Diabetes Care. 2014; 37:537-545 [S,II]
VALIDACIÓN EXTERNA DE LA FÓRMULA DE RIESGO UKPDS PARA LA APARICIÓN DE DIABETES TIPO 2: NECESIDAD DE NUEVAS ECUACIONES DE RIESGO ESPECÍFICAS DE LA DIABETES TIPO 2
 
Ding M, Bhupathiraju SN, Chen M, van Dam RM, Hu FB. Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose-response meta-analysis. Diabetes Care. 2014; 37:569-586 [M,I]
CONSUMO DE CAFÉ CON CAFEÍNA Y SIN CAFEÍNA Y RIESGO DE DIABETES TIPO 2: REVISIÓN SISTEMÁTICA Y METAANÁLISIS DE RESPUESTA A LA DOSIS
 
 
Churton S1, Brown L, Shin TM, Korman NJ. Does treatment of psoriasis reduce the risk of cardiovascular disease? Drugs. 2014; 74:169-182 [R,I]
¿REDUCE EL TRATAMIENTO DE LA PSORIASIS EL RIESGO DE ENFERMEDAD CARDIOVASCULAR?
 
Liao TV1, Phan SV. Acute hyperglycemia associated with short-term use of atypical antipsychotic medications. Drugs. 2014; 74:183-194 [R,II]
HIPERGLUCEMIA AGUDA ASOCIADA AL USO A CORTO PLAZO DE MEDICACIÓN ANTIPSICÓTICA
 
Plosker GL. Sitagliptin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014; 74:223-242 [R,I]
SITAGLIPTINA: REVISIÓN DE SU USO EN PACIENTES CON DIABETES MELLITUS TIPO 2
 
Burness CB1, Perry CM. Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism. Drugs. 2014; 74:243-262 [R,II]
RIVAROXABAN: REVISIÓN DE SU USO EN EL TRATAMIENTO DE LA TROMBOSIS VENOSA PROFUNDA O EN EL EMBOLISMO PULMONAR Y EN LA PREVENCIÓN DEL TROMBOEMBOLISMO VENOSO RECURRENTE
 
 
Liebetrau C, Nef HM, Hamm CW. Troponin: more lessons to learn. Eur Heart J. 2014; 35:338-340 [AO,I]
TROPONINA: MÁS LECCIONES QUE APRENDER
 
Working Group on the Summit on Combination Therapy for CVD. Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. Eur Heart J. 2014; 35:353-364 [R,II]
FARMACOTERAPIA COMBINADA PARA PREVENIR LA ENFERMEDAD CARDIOVASCULAR: ESTADO PRESENTE Y RETOS
 
Filippatos G, Farmakis D, Parissis J. Renal dysfunction and heart failure: things are seldom what they seem. Eur Heart J. 2014; 35:416-418 [AO,I]
DISFUNCIÓN RENAL E INSUFICIENCIA CARDIACA: LAS COSAS RARA VEZ SON LO QUE PARECEN
 
Volpe M, Rubattu S, Burnett J Jr. Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J. 2014; 35:419-425 [R,II]
PÉPTIDOS NATRIURÉTICOS Y ENFERMEDADES CARDIOVASCULARES: USO ACTUAL Y PERSPECTIVAS
 
Ramsay SE, Whincup PH, Papacosta O, Morris RW, Lennon LT, Goya Wannamethee S. Inequalities in heart failure in older men: prospective associations between socioeconomic measures and heart failure incidence in a 10-year follow-up study. Eur Heart J. 2014; 35:442-447 [S,II]
DESIGUALDADES EN LA INSUFICIENCIA CARDIACA EN LOS ANCIANOS: ASOCIACIONES PROSPECTIVAS ENTRE MEDIDAS SOCIOECONÓMICAS E INCIDENCIA DE INSUFICIENCIA CARDIACA EN UN ESTUDIO DE SEGUIMIENTO DE 10 AÑOS
 
Ehrlich JR, Ovsyshcher E. Slowing down the heart rate in permanent atrial fibrillation. Eur Heart J. 2014; 35:480-481 [AO,I]
BAJAR LA FRECUENCIA CARDIACA EN LA FIBRILACIÓN AURICULAR PERMANENTE
 
Hindricks G, Packer DL. Moving catheter ablation forward from paroxysmal to persistent atrial fibrillation: progress, limitations, and surprises of the SARA trial. Eur Heart J. 2014; 35:482-484 [AO,I]
AVANZAR LA ABLACIÓN POR CATÉTER DESDE LA FIBRILACIÓN AURICULAR PAROXÍSTICA HACIA LA PERMANENTE: PROGRESO, LIMITACIONES Y SORPRESAS DEL ENSAYO SARA
 
Mont L, Bisbal F, Hernández-Madrid A, Pérez-Castellano N, Viñolas X, Arenal A, et al; SARA investigators. Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur Heart J. 2014; 35:501-507 [EC,II]
ABLACIÓN POR CATÉTER FRENTE A TRATAMIENTO ANTIARRÍTMICO FARMACOLÓGICO DE LA FIBRILACIÓN AURICULAR PERSISTENTE: ENSAYO MULTICÉNTRICO ALEATORIZADO CONTROLADO (ESTUDIO SARA)
 
Ulimoen SR, Enger S, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, et al. Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J. 2014; 35:517-524 [EC,II]
LOS BLOQUEADORES DE LOS CANALES DEL CALCIO MEJORAN LA CAPACIDAD DE EJERCICIO Y REDUCEN LOS NIVELES DE PÉPTIDO NATRIURÉTICO N-TERMINAL PRO TIPO B EN COMPARACIÓN CON LOS BETABLOQUEANTES EN PACIENTES CON FIBRILACIÓN AURICULAR PERMANENTE
 
 
Newton W1, Sutton M, Asher GN. The elephant in the room. Fam Med. 2014; 46:85-87 [AO,I]
EL ELEFANTE EN LA HABITACIÓN (Expresión inglesa semejante a la de "El traje nuevo del emperador", algo evidente de lo que nadie quiere hablar)
 
Clark RD1, Williams AA. Patient preferences in discussing sexual dysfunctions in primary care. Fam Med. 2014; 46:124-128 [T,I]
PREFERENCIAS DEL PACIENTE AL HABLAR DE LAS DISFUNCIONES SEXUALES EN ATENCIÓN PRIMARIA
 
 
Sebo P, Cerutti B, Haller DM. Effect of magnesium therapy on nocturnal leg cramps: a systematic review of randomized controlled trials with meta-analysis using simulations. Fam Pract. 2014; 31:7-19 [M,I]
EFECTO DEL TRATAMIENTO CON MAGNESIO SOBRE LOS CALAMBRES NOCTURNOS EN LAS PIERNAS: REVISIÓN SISTEMÁTICA DE ENSAYOS ALEATORIZADOS CONTROLADOS CON METAANÁLISIS USANDO SIMULACIONES
 
Ortega R, Garcia-Ortiz L, Torcal J, Echevarria P, Vargas-Machuca C, Gomez A, et al; ESCAP Group. Supervised exercise for acute coronary patients in primary care: a randomized clinical trial. Fam Pract. 2014; 31:20-29 [EC,I]
EJERCICIO SUPERVISADO PARA LOS PACIENTES CORONARIOS AGUDOS EN ATENCIÓN PRIMARIA: ENSAYO CLÍNICO ALEATORIZADO
 
Ryborg CT, Søndergaard J, Lous J, Munck A, Larsen PV, Thomsen JL. Quality of life in children with otitis media--a cohort study. Fam Pract. 2014; 31:30-37 [S,I]
CALIDAD DE VIDA EN NIÑOS CON OTITIS MEDIA: ESTUDIO DE COHORTE
 
Booth HP, Prevost AT, Gulliford MC. Impact of body mass index on prevalence of multimorbidity in primary care: cohort study. Fam Pract. 2014; 31:38-43 [S,I]
IMPACTO DEL ÍNDICE DE MASA CORPORAL SOBRE LA PREVALENCIA DE MULTIMORBILIDAD EN ATENCIÓN PRIMARIA: ESTUDIO DE COHORTE
 
 
Ma X, Zhang B, Zheng W. Genetic variants associated with colorectal cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Gut. 2014; 63:326-336 [M,II]
VARIANTES GENÉTICAS ASOCIADAS CON EL RIESGO DE CÁNCER COLORRECTAL: SINOPSIS DE INVESTIGACIÓN GLOBAL, METAANÁLISIS Y EVIDENCIA EPIDEMIOLÓGICA
 
 
Psaty BM, Weiss NS. 2013 ACC/AHA guideline on the treatment of blood cholesterol: a fresh interpretation of old evidence. JAMA. 2014; 311:461-462 [AO,II]
GUÍA ACC/AHA 2013 SOBRE EL TRATAMIENTO DEL COLESTEROL EN SANGRE: UNA INTERPRETACIÓN NUEVA DE UNA VIEJA EVIDENCIA
 
Ioannidis JP. More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines. JAMA. 2014; 311:463-464 [AO,II]
¿MÁS DE MIL MILLONES DE PERSONAS TOMANDO ESTATINAS?: IMPLICACIONES POTENCIALES DE LAS NUEVAS GUÍAS CARDIOVASCULARES
 
Montori VM, Brito JP, Ting HH. Patient-centered and practical application of new high cholesterol guidelines to prevent cardiovascular disease. JAMA. 2014; 311:465-466 [AO,II]
APLICACIÓN PRÁCTICA Y CENTRADA EN EL PACIENTE DE LAS NUEVAS GUÍAS DE COLESTEROL ALTO PARA PREVENIR LA ENFERMEDAD CARDIOVASCULAR
 
Saver JL. Blood pressure management in early ischemic stroke. JAMA. 2014; 311:469-470 [AO,I]
MANEJO DE LA PRESIÓN ARTERIAL EN EL ICTUS ISQUÉMICO PRECOZ
 
Sarafidis PA, Bakris GL. Early patterns of blood pressure change and future coronary atherosclerosis. JAMA. 2014; 311:471-472 [AO,I]
PAUTAS PRECOCES DE CAMBIO DE LA PRESIÓN ARTERIAL Y FUTURA ATEROSCLEROSIS CORONARIA
 
Sox HC. Assessing the trustworthiness of the guideline for management of high blood pressure in adults. JAMA. 2014; 311:472-474 [AO,I]
VALORAR LA FIABILIDAD DE LA GUÍA DE MANEJO DE LA PRESIÓN ARTERIAL ELEVADA EN ADULTOS
 
Peterson ED, Gaziano JM, Greenland P. Recommendations for treating hypertension: what are the right goals and purposes? JAMA. 2014; 311:474-476 [AO,II]
RECOMENDACIONES PARA TRATAR LA HIPERTENSIÓN: ¿CUÁLES SON LOS OBJETIVOS Y LOS PROPÓSITOS CORRECTOS?
 
Bauchner H, Fontanarosa PB, Golub RM. Updated guidelines for management of high blood pressure: recommendations, review, and responsibility. JAMA. 2014; 311:477-478 [AO,II]
GUÍAS ACTUALIZADAS PARA EL MANEJO DE LA PRESIÓN ARTERIAL ELEVADA: RECOMENDACIONES, REVISIÓN Y RESPONSABILIDAD
 
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311:507-520 [M,III]
GUÍA BASADA EN LA EVIDENCIA PARA EL MANEJO DE LA PRESIÓN ARTERIAL ELEVADA EN ADULTOS: INFORME DE LOS MIEMBROS DEL COMITÉ DESIGNADOS PARA EL JNC 8
 
Hanson M. Understanding the origins of diabetes. JAMA. 2014; 311:575-576 [AO,I]
COMPRENDER LOS ORÍGENES DE LA DIABETES
 
Small GW. Treating dementia and agitation. JAMA. 2014; 311:677-678 [AO,I]
TRATAR LA DEMENCIA Y LA AGITACIÓN
 
Calkins H. Has the time come to recommend catheter ablation of atrial fibrillation as first-line therapy? JAMA. 2014; 311:679-680 [AO,I]
¿HA LLEGADO LA HORA DE RECOMENDAR LA ABLACIÓN MEDIANTE CATÉTER COMO TRATAMIENTO DE PRIMERA LÍNEA EN LA FIBRILACIÓN AURICULAR?
 
Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al; CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014; 311:682-691 [EC,II]
EFECTO DEL CITALOPRAM SOBRE LA AGITACIÓN EN LA ENFERMEDAD DE ALZHEIMER: ENSAYO CLÍNICO ALEATORIZADO CitAD
 
Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J, et al; RAAFT-2 Investigators. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA. 2014; 311:692-700 [EC,II]
ABLACIÓN POR RADIOFRECUENCIA FRENTE A FÁRMACOS ANTIARRÍTMICOS COMO TRATAMIENTO DE PRIMERA LÍNEA DE LA FIBRILACIÓN AURICULAR PAROXÍSTICA (RAAFT-2): ENSAYO ALEATORIZADO
 
Wells PS, Forgie MA, Rodger MA. Treatment of venous thromboembolism. JAMA. 2014; 311:717-728 [R,II]
TRATAMIENTO DEL TROMBOEMBOLISMO VENOSO
 
Di Nisio M, Middeldorp S. Treatment of lower extremity superficial thrombophlebitis. JAMA. 2014; 311:729-730 [R,II]
TRATAMIENTO DE LA TROMBOFLEBITIS SUPERFICIAL DE LA EXTREMIDAD INFERIOR
 
Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014; 311:806-814 [T,I]
PREVALENCIA DE LA OBESIDAD INFANTIL Y DEL ADULTO EN LOS ESTADOS UNIDOS
 
Mody L, Juthani-Mehta M. Urinary tract infections in older women: a clinical review. JAMA. 2014; 311:844-854 [R,II]
INFECCIONES DE VÍAS URINARIAS BAJAS EN MUJERES MAYORES: REVISIÓN CLÍNICA
 
Drugs for urinary tract infections. JAMA. 2014; 311:855-856 [AO,I]
FÁRMACOS PARA INFECCIONES DE VÍAS URINARIAS
 
 
Liu P, Nikels M, Combs B. Diuretics and diarrhea: a dangerous combination: a teachable moment. JAMA Intern Med. 2014; 174:182 [AO,I]
DIURÉTICOS Y DIARREA: COMBINACIÓN PELIGROSA: MOMENTO DE ENSEÑANZA
 
Stergiopoulos K, Boden WE, Hartigan P, Möbius-Winkler S, Hambrecht R, Hueb W, et al. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative meta-analysis of contemporary randomized clinical trials. JAMA Intern Med. 2014; 174:232-240 [M,II]
RESULTADOS DE INTERVENCIONES CORONARIAS PERCUTÁNEAS EN PACIENTES CON ENFERMEDAD ARTERIAL CORONARIA OBSTRUCTIVA ESTABLE E ISQUEMIA DE MIOCARDIO: METAANÁLISIS DE COLABORACIÓN DE ENSAYOS CLÍNICOS ALEATORIZADOS CONTEMPORÁNEOS
 
Rubini M, Reiter M, Twerenbold R, Reichlin T, Wildi K, Haaf P, et al. Sex-specific chest pain characteristics in the early diagnosis of acute myocardial infarction. JAMA Intern Med. 2014; 174:241-249 [S,I]
CARACTERÍSTICAS ESPECÍFICAS POR SEXO DEL DOLOR TORÁCICO EN EL DIAGNÓSTICO PRECOZ DEL INFARTO AGUDO DE MIOCARDIO
 
Huang ES, Laiteerapong N, Liu JY, John PM, Moffet HH, Karter AJ. Rates of complications and mortality in older patients with diabetes mellitus: the Diabetes and Aging study.
JAMA Intern Med. 2014; 174:251-258 [S,II]
TASAS DE COMPLICACIONES Y MORTALIDAD EN PACIENTES MAYORES CON DIABETES MELLITUS: ESTUDIO DIABETES Y ENVEJECIMIENTO
 
Patz EF Jr, Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemägi MC, et al; NLST Overdiagnosis Manuscript Writing Team. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014; 174:269-274 [EC,II]
SOBREDIAGNÓSTICO EN EL CRIBAJE DE CÁNCER DE PULMÓN MEDIANTE TAC DE DOSIS BAJA
 
 
López-Torres J; en representación del Grupo ANVITAD. Efecto del calcio y la vitamina D en la reducción de caídas de las personas mayores: ensayo clínico aleatorizado frente a placebo. Med Clin (Barc). 2014; 142:95-102 [EC,II]
EFECTO DEL CALCIO Y LA VITAMINA D EN LA REDUCCIÓN DE CAÍDAS DE LAS PERSONAS MAYORES: ENSAYO CLÍNICO ALEATORIZADO FRENTE A PLACEBO
 
Formiga F, Perez-Maraver M. La diabetes mellitus tipo 2 en el paciente anciano. Es básico saber cómo individualizar. Med Clin (Barc). 2014; 142:114-115 [AO,I]
LA DIABETES MELLITUS TIPO 2 EN EL PACIENTE ANCIANO. ES BÁSICO SABER CÓMO INDIVIDUALIZAR
 
López-López J, Jané E, Chimenos E. Pronóstico y tratamiento de la boca seca. Revisión sistemática. Med Clin (Barc). 2014; 142:119-124 [M,I]
PRONÓSTICO Y TRATAMIENTO DE LA BOCA SECA. REVISIÓN SISTEMÁTICA
 
Aguilar FJ. Protocolo de tratamiento de la deficiencia de vitamina D. Med Clin (Barc). 2014; 142:125-131 [R,I]
PROTOCOLO DE TRATAMIENTO DE LA DEFICIENCIA DE VITAMINA D
 
Peláez-Fernández MA, Ruiz-Lázaro PM, Labrador FJ, Raich RM. Validación del Eating Attitudes Test como instrumento de cribado de trastornos de la conducta alimentaria en población general.
Med Clin (Barc). 2014; 142:153-155 [T,I]
VALIDACIÓN DEL EATING ATTITUDES TEST COMO INSTRUMENTO DE CRIBADO DE TRASTORNOS DE LA CONDUCTA ALIMENTARIA EN POBLACIÓN GENERAL
 
Trullàs JC, Morales-Rull JL, Formiga F; en representación del Grupo de Trabajo de Insuficiencia Cardiaca y Fibrilación Auricular de la Sociedad Española de Medicina Interna. Tratamiento diurético en la insuficiencia cardiaca. Med Clin (Barc). 2014; 142:163-170 [R,II]
TRATAMIENTO DIURÉTICO EN LA INSUFICIENCIA CARDIACA
 
Marco P, Zamorano JL, Chana F, Llau JV. Nuevas perspectivas clínicas en el uso de los anticoagulantes orales directos. Med Clin (Barc). 2014; 142:171-178 [R,II]
NUEVAS PERSPECTIVAS CLÍNICAS EN EL USO DE LOS ANTICOAGULANTES ORALES DIRECTOS
 
 
Elosua R. Las funciones de riesgo cardiovascular: utilidades y limitaciones. Rev Esp Cardiol. 2014; 67:77-79 [AO,I]
LAS FUNCIONES DE RIESGO CARDIOVASCULAR: UTILIDADES Y LIMITACIONES
 
Grupo de Trabajo de la SEC para la guía de la ESC 2013 sobre diagnóstico y tratamiento de la cardiopatía isquémica estable, revisores expertos para la guía de la ESC 2013 sobre diagnóstico y tratamiento de la cardiopatía isquémica estable y Comité de Guías de la SEC. Comentarios a la guía de práctica clínica de la ESC 2013 sobre diagnóstico y tratamiento de la cardiopatía isquémica estable. Rev Esp Cardiol. 2014; 67:80-86 [AO,II]
COMENTARIOS A LA GUÍA DE PRÁCTICA CLÍNICA DE LA ESC 2013 SOBRE DIAGNÓSTICO Y TRATAMIENTO DE LA CARDIOPATÍA ISQUÉMICA ESTABLE
 
Grupo de Trabajo de la SEC para la guía de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, revisores expertos para la guía de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular y Comité de Guías de la SEC - Comentarios a la guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular. Rev Esp Cardiol. 2014; 67:87-93 [AO,II]
COMENTARIOS A LA GUÍA DE PRÁCTICA CLÍNICA DE LA ESC SOBRE DIABETES, PREDIABETES Y ENFERMEDAD CARDIOVASCULAR
 
Brotons C, Moral I, Soriano N, Cuixart L, Osorio D, Bottaro D, et al. Impacto de la utilización de las diferentes tablas SCORE en el cálculo del riesgo cardiovascular. Rev Esp Cardiol. 2014; 67:94-100 [T,I]
IMPACTO DE LA UTILIZACIÓN DE LAS DIFERENTES TABLAS SCORE EN EL CÁLCULO DEL RIESGO CARDIOVASCULAR
 
Puig T, Ferrero-Gregori A, Roig E, Vazquez R, Gonzalez-Juanatey JR, Pascual-Figal D, et al; en representación de los investigadores de REDINSCOR. Valor pronóstico del índice de masa corporal y el perímetro de cintura en los pacientes con insuficiencia cardiaca crónica (Registro Español REDINSCOR) Rev Esp Cardiol. 2014; 67:101-106 [S,I]
VALOR PRONÓSTICO DEL ÍNDICE DE MASA CORPORAL Y EL PERÍMETRO DE CINTURA EN LOS PACIENTES CON INSUFICIENCIA CARDIACA CRÓNICA (REGISTRO ESPAÑOL REDINSCOR)
 
Sanchis J, Avanzas P, Bayes-Genis A, Pérez de Isla L, Heras M. Síndromes coronarios agudos: nuevas estrategias de diagnóstico y tratamiento. Rev Esp Cardiol. 2014; 67:138 [R,I]
SÍNDROMES CORONARIOS AGUDOS: NUEVAS ESTRATEGIAS DE DIAGNÓSTICO Y TRATAMIENTO
 
Ferreira-González I. Epidemiología de la enfermedad coronaria. Rev Esp Cardiol. 2014; 67:139-144 [R,I]
EPIDEMIOLOGÍA DE LA ENFERMEDAD CORONARIA
 
Grupo de Trabajo de la Sociedad Europea de Cardiología sobre diagnóstico y tratamiento de la cardiopatía isquémica estable. Guía de Práctica Clínica de la ESC 2013 sobre diagnóstico y tratamiento de la cardiopatía isquémica estable. Rev Esp Cardiol. 2014; 67:135.e1-e81 [M,II]
GUÍA DE PRÁCTICA CLÍNICA DE LA ESC 2013 SOBRE DIAGNÓSTICO Y TRATAMIENTO DE LA CARDIOPATÍA ISQUÉMICA ESTABLE
 
Grupo de Trabajo de diabetes, prediabetes y enfermedades cardiovasculares de la Sociedad Europea de Cardiología (ESC) y la European Association for the Study of Diabetes (EASD) Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. Rev Esp Cardiol. 2014; 67:136.e1-e56 [M,II]
GUÍA DE PRÁCTICA CLÍNICA DE LA ESC SOBRE DIABETES, PREDIABETES Y ENFERMEDAD CARDIOVASCULAR, EN COLABORACIÓN CON LA EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES
 
 
Tobacco control in the USA: an end to political mythology. Lancet. 2014; 383:384. [AO,I]
CONTROL DEL TABACO EN EE UU: FIN DE LA MITOLOGÍA POLÍTICA
 
Palliative care: a peaceful, humane global campaign is needed. Lancet. 2014; 383:487 [AO,I]
CUIDADOS PALIATIVOS: SE NECESITA UNA CAMPAÑA MUNDIAL HUMANA Y PACÍFICA
 
Hellard ME, Doyle JS. Interferon-free hepatitis C treatment: one pill to fit all? Lancet. 2014; 383:491-492 [AO,I]
TRATAMIENTO DE LA HEPATITIS SIN INTERFERÓN: ¿UNA PASTILLA SIRVE PARA TODO?
 
Isidean SD, Franco EL. Embracing a new era in cervical cancer screening. Lancet. 2014; 383:493-494 [AO,I]
ABRAZAR UNA NUEVA ERA EN EL CRIBAJE DE CÁNCER CERVICAL
 
Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al; International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014; 383:524-532 [EC,II]
EFICACIA DEL CRIBAJE BASADO EN VPH EN LA PREVENCIÓN DEL CÁNCER DE CÉRVIX INVASIVO: SEGUIMIENTO DE CUATRO ENSAYOS EUROPEOS CONTROLADOS ALEATORIZADOS
 
Vineis P, Wild CP. Global cancer patterns: causes and prevention. Lancet. 2014; 383:549-557 [R,II]
PATRONES MUNDIALES DEL CÁNCER: CAUSAS Y PREVENCIÓN
 
Hanahan D. Rethinking the war on cancer. Lancet. 2014; 383:558-563. doi [AO,II]
REPENSAR LA GUERRA CONTRA EL CÁNCER
 
Coleman MP. Cancer survival: global surveillance will stimulate health policy and improve equity. Lancet. 2014; 383:564-573 [R,II]
SUPERVIVENCIA EN EL CÁNCER: LA VIGILANCIA MUNDIAL ESTIMULARÁLA POLÍTICA SANITARIA Y MEJORARÁ LA EQUIDAD
 
Horton R, Lo S. Protecting health: the global challenge for capitalism. Lancet. 2014; 383:577-578 [AO,I]
PROTEGER LA SALUD: DESAFÍO MUNDIAL PARA EL CAPITALISMO
 
Johns EJ. Resistant hypertension and renal denervation: 3 years on. Lancet. 2014; 383:583-584 [AO,I]
HIPERTENSIÓN RESISTENTE Y DENERVACIÓN RENAL: 3 AÑOS DESPUÉS
 
Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 2014;383:622-629 [EC,II]
DENERVACIÓN RENAL PERCUTÁNEA EN PACIENTES CON HIPERTENSIÓN RESISTENTE AL TRATAMIENTO: INFORME FINAL A LOS 3 AÑOS DEL ESTUDIO SYMPLICITY HTN-1
 
Ottersen OP, Dasgupta J, Blouin C, Buss P, Chongsuvivatwong V, Frenk J, et al. The political origins of health inequity: prospects for change. Lancet. 2014; 383:630-667 [R,II]
ORÍGENES POLÍTICOS DE LA DESIGUALDAD SANITARIA: PERSPECTIVAS DE CAMBIO
 
Statins for millions more? Lancet. 2014; 383:669 [AO,I]
¿ESTATINAS PARA MÁS MILLONES DE PERSONAS?
 
Health in austerity: hard decisions for hard times. Lancet. 2014; 383:670 [AO,I]
SALUD EN LA AUSTERIDAD: DECISIONES DIFÍCILES PARA TIEMPOS DIFÍCILES
 
Kentikelenis A, Karanikolos M, Reeves A, McKee M, Stuckler D. Greece's health crisis: from austerity to denialism. Lancet. 2014; 383:748-753 [R,II]
CRISIS SANITARIA EN GRECIA: DE LA AUSTERIDAD A LA DENEGACIÓN SISTEMÁTICA
 
Gopinathan U, Cuadrado C, Watts N, Guinto RR, Hougendobler D, Wanjau W, et al. The political origins of health inequity: the perspective of the Youth Commission on Global Governance for Health. Lancet. 2014; 383:e12-e13 [R,II]
ORÍGENES POLÍTICOS DE LA DESIGUALDAD SANITARIA: PERSPECTIVA DE LA YOUTH COMMISSION ON GLOBAL GOVERNANCE FOR HEALTH
 
 
Fauci AS1, Marston HD. Ending AIDS--is an HIV vaccine necessary? N Engl J Med. 2014; 370:495-498 [AO,I]
ACABAR CON EL SIDA ¿ES NECESARIA UNA VACUNA PARA VIH?
 
Patel V, Saxena S. Transforming lives, enhancing communities--innovations in global mental health. N Engl J Med. 2014; 370:498-501 [AO,I]
TRANSFORMAR VIDAS, REFORZAR COMUNIDADES: INNOVACIONES EN LA SALUD MENTAL MUNDIAL
 
Wunderink RG, Waterer GW. Clinical practice. Community-acquired pneumonia. N Engl J Med. 2014; 370:543-551 [R,I]
PRÁCTICA CLÍNICA. NEUMONÍA ADQUIRIDA EN LA COMUNIDAD
 
Warner M, Gustafsson JA. On estrogen, cholesterol metabolism, and breast cancer. N Engl J Med. 2014; 370:572-573 [AO,I]
SOBRE ESTRÓGENO, METABOLISMO DEL COLESTEROL Y CÁNCER DE MAMA
 
Morden NE, Colla CH, Sequist TD, Rosenthal MB. Choosing wisely--the politics and economics of labeling low-value services. N Engl J Med. 2014; 370:589-592 [AO,I]
ESCOGER CON SABIDURÍA: LA POLÍTICA Y LA ECONOMÍA DEL ETIQUETADO DE LOS SERVICIOS DE POCO VALOR
 
Allen RP, Chen C, Garcia-Borreguero D, Polo O, DuBrava S, Miceli J, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014; 370:621-631 [EC,I]
COMPARACIÓN DE PREGABALINA CON PRAMIPEXOL PARA EL SÍNDROME DE PIERNAS INQUIETAS
 
Tarlo SM, Lemiere C. Occupational asthma. N Engl J Med. 2014; 370:640-649 [R,I]
ASMA OCUPACIONAL
 
Chokroverty S. Therapeutic dilemma for restless legs syndrome. N Engl J Med. 2014; 370:667-668 [AO,I]
DILEMA TERAPÉUTICO EN EL SÍNDROME DE PIERNAS INQUIETAS
 
Mechanic R. Post-acute care--the next frontier for controlling Medicare spending. N Engl J Med. 2014; 370:692-694 [AO,I]
CUIDADOS POSTAGUDOS: LA PRÓXIMA FRONTERA PARA CONTROLAR LOS GASTOS DE MEDICARE
 
Reuben DB, Tinetti ME. The hospital-dependent patient. N Engl J Med. 2014; 370:694-697 [AO,I]
EL PACIENTE HOSPITALODEPENDIENTE
 
Bohadana A, Izbicki G, Kraman SS. Fundamentals of lung auscultation. N Engl J Med. 2014; 370:744-751 [R,I]
FUNDAMENTOS DE AUSCULTACIÓN PULMONAR
 
Bunn HF. Vitamin B12 and pernicious anemia--the dawn of molecular medicine. N Engl J Med. 2014; 370:773-776 [AO,I]
VITAMINA B12 Y ANEMIA PERNICIOSA: EL AMANECER DE LA MEDICINA MOLECULAR
 
Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med 2014; 370:794-797 [M,II]
SEGURIDAD PANCREÁTICA DE LOS FÁRMACOS BASADOS EN INCRETINAS: VALORACIÓN DE LA FDA Y LA EMA
 
Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF, et al; CARE Study Group. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med. 2014; 370:799-808 [T,I]
SECUENCIACIÓN DE ADN FRENTE AL CRIBAJE ANEUPLOIDE ESTÁNDAR PRENATAL
 
Feldman HM, Reiff MI. Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents. N Engl J Med. 2014; 370:838-846 [R,I]
PRÁCTICA CLÍNICA. TRASTORNO DE HIPERACTIVIDAD-DÉFICIT DE ATENCIÓN EN NIÑOS Y ADOLESCENTES
 
Greene MF, Phimister EG. Screening for trisomies in circulating DNA. N Engl J Med. 2014; 370:874-875 [AO,I]
CRIBAJE DE TRISOMÍAS POR ADN CIRCULANTE
 
Maitland K. New diagnostics for common childhood infections. N Engl J Med. 2014; 370:875-877 [AO,I]
NUEVOS DIAGÓSTICOS PARA LAS INFECCIONES COMUNES INFANTILES
 
 
Lazarinis N, Jørgensen L, Ekström T, Bjermer L, Dahlén B, Pullerits T, et al. Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax. 2014; 69:130-136 [EC,II]
LA COMBINACIÓN DE BUDESONIDA/FORMOTEROL BAJO DEMANDA MEJORA EL CONTROL DEL ASMA REDUCIENDO LA BRONCOCONSTRICCIÓN INDUCIDA POR EL EJERCICIO
 
ACADEMIC MEDICINE
 
Two reports in this issue address the important topic of clinical decision making. Dual process theory has emerged as the dominant model for understanding the complex processes that underlie human decision making. This theory distinguishes between the reflexive, autonomous processes that characterize intuitive decision making and the deliberate reasoning of an analytical approach. In this commentary, the authors address the polarization of viewpoints that has developed around the relative merits of the two systems. Although intuitive processes are typically fast and analytical processes slow, speed alone does not distinguish them. In any event, the majority of decisions in clinical medicine are not dependent on very short response times. What does appear relevant to diagnostic ease and accuracy is the degree to which the symptoms of the disease being diagnosed are characteristic ones.There are also concerns around some methodological issues related to research design in this area of enquiry. Reductionist approaches that attempt to isolate dependent variables may create such artificial experimental conditions that both external and ecological validity are sacrificed. Clinical decision making is a complex process with many independent (and interdependent) variables that need to be separated out in a discrete fashion and then reflected on in real time to preserve the fidelity of clinical practice. With these caveats in mind, the authors believe that research in this area should promote a better understanding of clinical practice and teaching by focusing less on the deficiencies of intuitive and analytical systems and more on their adaptive strengths.
The last 20 years have seen an unprecedented technological revolution, including the development of the personal computer. The new technologies that have emerged during this age of innovation have allowed human beings to connect widely with one another through electronic media and have made life more efficient and streamlined. Likewise, this technological renaissance has helped to define medicine as one of the most innovative professions by providing physicians with diagnostics and interventions that are more accurate, efficacious, and safe, to the benefit of physicians and the public. However, in both life and the practice of medicine, these new technologies have had the unintended consequence of reducing the value of direct human connection and threaten to isolate individuals in spite of advancing society.In this commentary, the author argues that human beings need to make a more concerted effort to connect with each other through both enhanced communication technologies and direct human contact. Likewise, leaders in medicine need to embrace and promote technological advancement while at the same time working to maintain the human connection that physicians have with their patients and teaching learners to do the same. Doing so will prevent physicians from becoming automated medical kiosks that offer sound, innovative medical advice but that lack the personality, compassion, and emotion that will lead to better health.
 
ANNALS OF INTERNAL MEDICINE
 
Conclusion: The cost of mammography varies by at least $8 billion per year on the basis of screening strategy. The USPSTF guidelines are based on the scientific evidence to date to maximize patient benefit and minimize harm but also result in far more effective use of resources.
 
Conclusion: Fecal immunochemical tests are moderately sensitive, are highly specific, and have high overall diagnostic accuracy for detecting CRC. Diagnostic performance of FITs depends on the cutoff value for a positive test result.
 
Conclusion: Genotype-guided personalization may improve the cost-effectiveness of prasugrel and ticagrelor after percutaneous coronary intervention for ACS, but ticagrelor for all patients may be an economically reasonable alternative in some settings.
 
Conclusion: Rituximab did not alleviate symptoms or disease activity in patients with pSS at week 24, although it alleviated some symptoms at earlier time points.
 
Recommendation: The USPSTF recommends that primary care providers screen women who have family members with breast, ovarian, tubal, or peritoneal cancer with 1 of several screening tools designed to identify a family history that may be associated with an increased risk for potentially harmful mutations in breast cancer susceptibility genes (BRCA1 or BRCA2). Women with positive screening results should receive genetic counseling and, if indicated after counseling, BRCA testing. (B recommendation)The USPSTF recommends against routine genetic counseling or BRCA testing for women whose family history is not associated with an increased risk for potentially harmful mutations in the BRCA1 or BRCA2 genes. (D recommendation)
 
 
ARCHIVOS DE BRONCONEUMOLOGIA
 
El 18,3% fueron pacientes nunca fumadores. Se diagnosticaron mayoritariamente en mujeres, estadios avanzados y estirpe histológica adenocarcinoma. No hubo diferencias de supervivencia con el grupo de fumadores.
 
ATENCION PRIMARIA
 
Una de las estrategias de promoción de la salud es el desarrollo de habilidades para la vida considerando a las propias personas como principal recurso para la salud. Un taller ha de conseguir que sus participantes se conviertan en «activos» para tomar decisiones y generar salud, centrándose en el desarrollo y adquisición de habilidades en grupo de una manera motivadora y con la finalidad de alcanzar unos objetivos. Los conceptos que fundamentan el diseño de un taller y que han de plantearse como etapa 0 son: planificación participativa, capacitar, aprendizaje significativo, aprender en grupo y técnicas participativas.
Las etapas que se deben seguir para diseñar un taller y facilitar su aplicación son: etapa 0 de fundamentación, etapa inicial, de acogida y de evaluación inicial; etapa central o de construcción del aprendizaje basado en la adquisición de conocimientos, actitudes y habilidades, y etapa final o de evaluación.
El médico de AP realiza el primer contacto de la mayoría de FA y deriva el 55% de los casos al servicio de urgencias hospitalario donde se inician la mayoría de tratamientos específicos de la FA.
El perfil profesional del médico de familia es diverso y dependiente del contexto variable, y no se deriva directamente de la teoría externa de la medicina de familia.
Hypertension was the most prevalent cardiovascular risk factor in the Catalan population attended at primary care centers. About two thirds of individuals with hypertension or DM2 were adequately controlled; hypercholesterolemia control was particularly low.
Existe gran heterogeneidad en la metodología empleada para la actividad de la conciliación. No existe ningún trabajo realizado específicamente en el paciente pluripatológico, que por su complejidad y susceptibilidad a errores de conciliación requiere una metodología estandarizada.
 
BRITISH JOURNAL OF PSYCHIATRY
 
Psychological medicine (liaison psychiatry) aims to integrate psychiatry into other areas of medicine. It is currently enjoying considerable expansion. The degree to which it can take advantage of this opportunity will be important not only for its own future, but also for the survival of psychiatry as a medical discipline.
Psychiatric diagnosis is in the spotlight following the recent publication of DSM-5. In this article we consider both the benefits and limitations of diagnosis in psychiatry. The use of internationally recognised diagnoses, although insufficient alone, is part of a psychiatrist's professional responsibility to provide high-quality, evidence-based care for patients.
Supervised benzodiazepine withdrawal augmented with psychotherapy should be considered in older people, although pragmatic reasons may necessitate consideration of other strategies such as medication review.
Transsexualism is not usually indicative of psychopathology. In carefully selected individuals, with multidisciplinary support, a change of social gender role and cross-sex hormone treatment greatly improves the psychological and social state. Sustained improvement merits gender reassignment surgery. The key is early referral with subsequent primary care cooperation in the treatment plan.
 
BRITISH MEDICAL JOURNAL
 
Increases in medical treatments accounted for almost half of the large recent decline in mortality due to coronary heart disease in Scotland. Furthermore, the Scottish National Health Service seems to have delivered these benefits equitably. However, the substantial contributions from population falls in blood pressure and other risk factors were diminished by adverse trends in obesity and diabetes. Additional population-wide interventions are urgently needed to reduce coronary heart disease mortality and inequalities in future decades.
Lower dose opioids are not associated with increased admissions or deaths in patients with COPD and might be safe for symptom reduction in severe respiratory disease.
Impaired first trimester fetal growth is associated with an adverse cardiovascular risk profile in school age children. Early fetal life might be a critical period for cardiovascular health in later life.
Annual mammography in women aged 40-59 does not reduce mortality from breast cancer beyond that of physical examination or usual care when adjuvant therapy for breast cancer is freely available. Overall, 22% (106/484) of screen detected invasive breast cancers were over-diagnosed, representing one over-diagnosed breast cancer for every 424 women who received mammography screening in the trial.
Following the removal of incentives, levels of performance across a range of clinical activities generally remained stable. This indicates that health benefits from incentive schemes can potentially be increased by periodically replacing existing indicators with new indicators relating to alternative aspects of care. However, all aspects of care investigated remained indirectly or partly incentivised in other indicators, and further work is needed to assess the generalisability of the findings when incentives are fully withdrawn.
Smoking cessation is associated with reduced depression, anxiety, and stress and improved positive mood and quality of life compared with continuing to smoke. The effect size seems as large for those with psychiatric disorders as those without. The effect sizes are equal or larger than those of antidepressant treatment for mood and anxiety disorders.
This study suggests that women who are positive for BRCA mutations and who are treated for stage I or II breast cancer with bilateral mastectomy are less likely to die from breast cancer than women who are treated with unilateral mastectomy. Given the small number of events in this cohort, further research is required to confirm these findings.
Neuropathic pain can develop after nerve injury, when deleterious changes occur in injured neurons and along nociceptive and descending modulatory pathways in the central nervous system. The myriad neurotransmitters and other substances involved in the development and maintenance of neuropathic pain also play a part in other neurobiological disorders. This might partly explain the high comorbidity rates for chronic pain, sleep disorders, and psychological conditions such as depression, and why drugs that are effective for one condition may benefit others. Neuropathic pain can be distinguished from non-neuropathic pain by two factors. Firstly, in neuropathic pain there is no transduction (conversion of a nociceptive stimulus into an electrical impulse). Secondly, the prognosis is worse: injury to major nerves is more likely than injury to non-nervous tissue to result in chronic pain. In addition, neuropathic pain tends to be more refractory than non-neuropathic pain to conventional analgesics, such as non-steroidal anti-inflammatory drugs and opioids. However, because of the considerable overlap between neuropathic and nociceptive pain in terms of mechanisms and treatment modalities, it might be more constructive to view these entities as different points on the same continuum. This review focuses on the mechanisms of neuropathic pain, with special emphasis on clinical implications.
 
CIRCULATION
 
Some insomnia symptoms, especially difficulty initiating asleep and nonrestorative sleep, are associated with a modestly higher risk of mortality.
AAA mortality has not declined globally, and this study reveals that differences between nations can be explained by variations in traditional cardiovascular risk factors. Declines in smoking prevalence correlate most closely with declines in AAA mortality, and a novel obesity paradox has been identified that requires further investigation. Public health measures could therefore further reduce global AAA mortality, with greatest benefits in the younger age group.
For women with discordant LDL-related measures, coronary risk may be underestimated or overestimated when LDL-C alone is used.
Among white JUPITER participants treated with potent statin therapy, Lp(a) was a significant determinant of residual risk. The magnitude of relative risk reduction with rosuvastatin was similar among participants with high or low Lp(a).
Dabigatran has similar effects on VTE recurrence and a lower risk of bleeding compared with warfarin for the treatment of acute VTE.
These findings provide evidence of progressive increases in overall burden, incidence, prevalence, and AF-associated mortality between 1990 and 2010, with significant public health implications. Systematic, regional surveillance of AF is required to better direct prevention and treatment strategies.
This study supports an association between PM2.5 and incident hypertension.
 
DIABETES CARE
 
CRF markedly modifies the relationship between adiposity and mortality in persons with prediabetes. Unfit individuals have a higher and fit individuals have a lower mortality risk irrespective of adiposity level in this high-risk group.
Magnesium intake may be particularly beneficial in offsetting risk of developing diabetes among those at high risk. Magnesium's long-term associations with non-steady-state (dynamic) measures deserve further research.
Both intensive insulin strategies improved glycemic control; however, final HbA1c levels were seen above those achieved in previous treat-to-target trials, likely due to the inadequate insulin titrations and probably due to the complexity of tested insulin regimens. A higher percentage of patients achieved target HbA1c <7% with multiple premixed insulins, but this treatment resulted in more nocturnal hypoglycemia than a basal-bolus regimen.
Diabetes, one of the leading chronic diseases in childhood, affects >190,000 (1 of 433) youth aged <20 years in the U.S., with racial and ethnic disparities seen in diabetes prevalence, overall and by diabetes type.
Coffee consumption was inversely associated with the risk of type 2 diabetes in a dose-response manner. Both caffeinated and decaffeinated coffee was associated with reduced diabetes risk.
The UKPDS stroke equations showed calibration ranging from poor to moderate; however, the CHD equations showed poor calibration and considerably overestimated CHD risk. There is a need for revised risk equations in type 2 diabetes.
Our results suggest that severe episodes of hypoglycemia are associated with an increased risk of severe ventricular arrhythmias.
The relationship between cognitive impairment and hypoglycemia appeared complex, with severe hypoglycemia associated with both poorer initial cognitive ability and accelerated cognitive decline.
Quarterly visits and GHb testing are associated with glycemic control in youth with type 1 diabetes.
 
DRUGS
 
Rivaroxaban (Xarelto(®)), an oral direct factor Xa inhibitor, is approved for the initial treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the prevention of recurrent DVT and PE. It is administered at a fixed oral dose and does not require routine coagulation monitoring. In the EINSTEIN-DVT and EINSTEIN-PE trials, in over 8,000 patients with DVT and/or PE, a single-drug approach with rivaroxaban was shown to be noninferior to standard therapy consisting of subcutaneous enoxaparin sodium overlapping with and followed by an oral dose-adjusted vitamin K antagonist (enoxaparin-VKA) with regard to the incidence of symptomatic recurrent venous thromboembolism (VTE) after 3, 6 or 12 months of treatment. Rivaroxaban was generally well tolerated in patients with DVT or PE, with no significant between-group differences in clinically relevant bleeding between the rivaroxaban and enoxaparin-VKA groups. Notably, rivaroxaban was associated with a significantly lower rate of major bleeding compared with enoxaparin-VKA when EINSTEIN-DVT and EINSTEIN-PE data were pooled. Pharmacoeconomic analyses indicated that rivaroxaban may be a cost-effective alternative to enoxaparin-VKA for the treatment of DVT or PE and prevention of recurrent VTE. Extended prophylaxis with rivaroxaban reduced the incidence of symptomatic recurrent VTE to a greater extent than placebo in the EINSTEIN-Extension trial, but was associated with a non-significant increase in the risk of clinically relevant bleeding compared with placebo. In conclusion, rivaroxaban is a reasonable alternative to standard therapy for the treatment of DVT and PE, and as extended thromboprophylaxis.
Psoriasis is an inflammatory disease associated with multiple comorbidities and cardiovascular risk factors. Patients with psoriasis have an increased risk of cardiovascular disease (CVD) and cardiovascular death. It has been proposed that overlapping mechanisms of systemic inflammation contribute to the link between psoriasis and cardiovascular disease. Some psoriasis treatments decrease systemic inflammation, but the effect of psoriasis treatments on heart disease is unknown. In this review of 23 original research publications, we present preliminary evidence that some psoriasis therapies improve cardiovascular biomarkers and the incidence of cardiovascular risk. Phototherapy may reduce some inflammatory cytokines, but there is little evidence for a decreased risk of CVD outcomes. Both methotrexate and tumour necrosis factor-a inhibitors improve cardiovascular inflammatory biomarkers and improve CVD outcomes. Short-term data on interleukin-12/23 inhibitors are varied, but most data suggest there is not an increase in cardiovascular events.
Sitagliptin (Januvia(®), Xelevia™, Glactiv(®), Tesavel(®)) is an orally administered, potent and highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4) and was the first agent of its class to be approved for use in the management of adults with type 2 diabetes. Numerous randomized placebo- or active comparator-controlled trials have demonstrated the efficacy of sitagliptin in terms of improving glycaemic control in patients with type 2 diabetes, including its use as monotherapy, initial combination therapy (usually with fixed-dose combinations of sitagliptin/metformin), or add-on therapy to metformin or to other antihyperglycaemic drugs, with or without metformin. The primary endpoint of the clinical trials was the reduction from baseline in glycosylated haemoglobin (HbA1c), although sitagliptin also showed beneficial effects for other endpoints, such as the proportion of patients who achieved target HbA1c, and reductions from baseline in fasting plasma glucose (FPG) levels and 2-h postprandial glucose (PPG) levels. Sitagliptin was generally well tolerated in clinical trials, had a low risk of hypoglycaemia (although this depends on background therapy) and had a neutral effect on body weight. Despite concerns regarding a possible increased risk of rare pancreatic adverse events (e.g. pancreatitis) with glucagon-like peptide-1 (GLP-1)-based therapies, such as GLP-1 receptor agonists and DPP-4 inhibitors, no causal association has been found; regulators in Europe recently conducted a review of available data, concluding that there is little evidence that these drugs could cause pancreatic inflammation or pancreatic cancer. A similar review is planned in the USA and postmarketing surveillance will continue. Thus, oral sitagliptin is an effective and generally well tolerated treatment option for the management of patients with type 2 diabetes.
The prevalence of metabolic disturbances associated with long-term use of antipsychotic medications has been widely reported in the literature. The use of atypical antipsychotics for the treatment of delirium in the intensive care unit (ICU) has gained popularity due to a lower potential for adverse effects compared with conventional antipsychotics. However, current studies evaluating safety and efficacy of antipsychotics in the ICU setting do not include metabolic parameters as a potential adverse effect that requires monitoring. It is thought that long-term adverse effects of antipsychotics may be out of context for the intensive care setting. A literature review was conducted to investigate the prevalence of acute hyperglycemia associated with short-term use of antipsychotics, with the purpose of reviewing evidence that hyperglycemia may occur even with short-term use of atypical antipsychotics. A MEDLINE search for acute hyperglycemia from short-term use of antipsychotics resulted in studies involving animal models and healthy volunteers. These studies indicate that acute hyperglycemia may occur after short-term treatment. A review of the literature shows preliminary evidence to suggest that atypical antipsychotics impact glucose sensitivity and induce insulin resistance even after a single dose. Although no studies have been conducted evaluating the impact of hyperglycemia in critically ill patients from the short-term use of atypical antipsychotics for the treatment of delirium, the potential to affect clinical outcomes exist and warrants further research in this area.
 
EUROPEAN HEART JOURNAL
 
Catheter ablation is superior to medical therapy for the maintenance of sinus rhythm in patients with persistent AF at 12-month follow-up.
Combination pills containing aspirin, multiple blood pressure (BP) lowering drugs, and a statin have demonstrated safety, substantial risk factor reductions, and improved medication adherence in the prevention of cardiovascular disease (CVD). The individual medications in combination pills are already recommended for use together in secondary CVD prevention. Therefore, current information on their pharmacokinetics, impact on the risk factors, and tolerability should be sufficient to persuade regulators and clinicians to use fixed-dose combination pills in high-risk individuals, such as in secondary prevention. Long-term use of these medicines, in a polypill or otherwise, is expected to reduce CVD risk by at least 50-60% in such groups. This risk reduction needs confirmation in prospective randomized trials for populations for whom concomitant use of the medications is not currently recommended (e.g. primary prevention). Given their additive benefits, the combined estimated relative risk reduction (RRR) in CVD from both lifestyle modification and a combination pill is expected to be 70-80%. The first of several barriers to the widespread use of combination therapy in CVD prevention is physician reluctance to use combination pills. This reluctance may originate from the belief that lifestyle modification should take precedence, and that medications should be introduced one drug at a time, instead of regarding combination pills and lifestyle modification as complementary and additive. Second, widespread availability of combination pills is also impeded by the reluctance of large pharmaceutical companies to invest in development of novel co-formulations of generic (or 'mature') drugs. A business model based on 'mass approaches' to drug production, packaging, marketing, and distribution could make the combination pill available at an affordable price, while at the same time providing a viable profit for the manufacturers. A third barrier is regulatory approval for novel multidrug combination pills, as there are few precedents for the approval of combination products with four or more components for CVD. Acceptance of combination therapy in other settings suggests that with concerted efforts by academics, international health agencies, research funding bodies, governments, regulators, and pharmaceutical manufacturers, combination pills for prevention of CVD in those with disease or at high risk (e.g. those with multiple risk factors) can be made available worldwide at affordable prices. It is anticipated that widespread use of combination pills with lifestyle modifications can lead to substantial risk reductions (as much as an 80% estimated RRR) in CVD. Heath care systems need to deploy these strategies widely, effectively, and efficiently. If implemented, these strategies could avoid several millions of fatal and non-fatal CVD events every year worldwide.
Rate-reducing treatment with diltiazem or verapamil preserved exercise capacity and reduced levels of NT-proBNP compared with baseline, whereas treatment with metoprolol or carvedilol reduced the exercise capacity and increased levels of NT-proBNP.
The natriuretic peptides (NPs) family, including atrial, B-type, and C-type NPs, is a group of hormones possessing relevant haemodynamic and anti-remodelling actions in the cardiovascular (CV) system. Due to their diuretic, natriuretic, vasorelaxant, anti-proliferative, and anti-hypertrophic effects, they are involved in the pathogenic mechanisms leading to major CV diseases, such as heart failure (HF), coronary artery disease, hypertension and left ventricular hypertrophy, and cerebrovascular accidents. Blood levels of NPs have established predictive value in the diagnosis of HF, as well as for its prognostic stratification. In addition, they provide useful clinical information in hypertension and in both stable and unstable coronary artery disease. Structural abnormalities of atrial natriuretic peptide gene (NPPA), as well as genetically induced changes in circulating levels of NPs, have a pathogenic causal link with CV diseases and represent emerging markers of CV risk. Novel NP-based therapeutic strategies are currently under advanced clinical development, as they are expected to contribute to the future management of hypertension and HF. The present review provides a current appraisal of NPs' clinical implications and a critical perspective of the potential therapeutic impact of pharmacological manipulation of this class of CV hormones.
Heart failure risk in older men was greater in the most deprived socioeconomic groups, which was only partly explained by established risk factors for HF. Novel risk factors contribute little to the associated risk.
 
FAMILY MEDICINE
 
Participants preferred discussions about SDs with PCPs through various means (ie, medical history forms, medical appointments). Although participants were divided on who (patient versus PCP) should start conversations about SDs, the majority of participants did not object to PCPs inquiring about SDs during office visits or on medical history forms. Patients in poorer health and with self-reported SDs may need PCPs to inquire about SDs. Recommendations to improve health care delivery are suggested, including PCPs inquiring about SDs with all patients, especially with individuals in poorer health or with histories of SDs.
 
FAMILY PRACTICE
 
Multiple morbidity is highly associated with increasing BMI category and obesity, highlighting the potential for targeted primary and secondary prevention interventions in primary care.
HRQOL in children with otitis media was significantly improved after 13 months. The improvement in HRQOL was significantly lower for children with sleep problems. The improvement in HRQOL was significantly lower in children whose parents had been absent from work due to the child's otitis media. There were no statistically significant differences in the improvement of HRQOL in children who had received a VT during the follow-up period.
A cycle ergometer exercise program supervised by primary care nurses increased the functional capacity of coronary patients more than unsupervised walking with a clinically relevant difference.
Magnesium therapy does not appear to be effective in the treatment of NLC in the general population, but may have a small effect in pregnant women. Further research using better designed RCTs is necessary.
 
GUT
 
Approximately 4% of genetic variants evaluated to date in candidate-gene association studies showed moderate to strong cumulative epidemiological evidence of an association with CRC risk. These genetic variants, if confirmed, may explain approximately 5% of familial CRC risk.
 
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
 
Hypertension is the most common condition seen in primary care and leads to myocardial infarction, stroke, renal failure, and death if not detected early and treated appropriately. Patients want to be assured that blood pressure (BP) treatment will reduce their disease burden, while clinicians want guidance on hypertension management using the best scientific evidence. This report takes a rigorous, evidence-based approach to recommend treatment thresholds, goals, and medications in the management of hypertension in adults. Evidence was drawn from randomized controlled trials, which represent the gold standard for determining efficacy and effectiveness. Evidence quality and recommendations were graded based on their effect on important outcomes. There is strong evidence to support treating hypertensive persons aged 60 years or older to a BP goal of less than 150/90 mm Hg and hypertensive persons 30 through 59 years of age to a diastolic goal of less than 90 mm Hg; however, there is insufficient evidence in hypertensive persons younger than 60 years for a systolic goal, or in those younger than 30 years for a diastolic goal, so the panel recommends a BP of less than 140/90 mm Hg for those groups based on expert opinion. The same thresholds and goals are recommended for hypertensive adults with diabetes or nondiabetic chronic kidney disease (CKD) as for the general hypertensive population younger than 60 years. There is moderate evidence to support initiating drug treatment with an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, calcium channel blocker, or thiazide-type diuretic in the nonblack hypertensive population, including those with diabetes. In the black hypertensive population, including those with diabetes, a calcium channel blocker or thiazide-type diuretic is recommended as initial therapy. There is moderate evidence to support initial or add-on antihypertensive therapy with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in persons with CKD to improve kidney outcomes. Although this guideline provides evidence-based recommendations for the management of high BP and should meet the clinical needs of most patients, these recommendations are not a substitute for clinical judgment, and decisions about care must carefully consider and incorporate the clinical characteristics and circumstances of each individual patient.
Among patients with probable Alzheimer disease and agitation who were receiving psychosocial intervention, the addition of citalopram compared with placebo significantly reduced agitation and caregiver distress; however, cognitive and cardiac adverse effects of citalopram may limit its practical application at the dosage of 30 mg per day.
Overall, there have been no significant changes in obesity prevalence in youth or adults between 2003-2004 and 2011-2012. Obesity prevalence remains high and thus it is important to continue surveillance.
Among patients with paroxysmal AF without previous antiarrhythmic drug treatment, radiofrequency ablation compared with antiarrhythmic drugs resulted in a lower rate of recurrent atrial tachyarrhythmias at 2 years. However, recurrence was frequent in both groups.
Establishing a diagnosis of symptomatic UTI in older women requires careful clinical evaluation with possible laboratory assessment using urinalysis and urine culture. Asymptomatic bacteriuria should be differentiated from symptomatic UTI. Asymptomatic bacteriuria in older women should not be treated.
Fondaparinux (2.5 mg) subcutaneously once daily for 45 days is associated with fewer symptomatic VTEs and lower rates of superficial venous thrombosis extension and recurrence with no increases in major bleeding compared with placebo. Low-molecular-weight heparin and nonsteroidal anti-inflammatory drugs are associated with lower rates of superficial thrombophlebitis extension or recurrence, but data regarding symptomatic VTEs are inconclusive.
The mainstay of VTE treatment is anticoagulation, while interventions such as thrombolysis and inferior vena cava filters are reserved for limited circumstances. Multiple therapeutic modes and options exist for VTE treatment with small but nonetheless important differential effects to consider. Anticoagulants will probably always increase bleeding risk, necessitating tailored treatment strategies that must incorporate etiology, risk, benefit, cost, and patient preference. Although great progress has been made, further study to understand individual patient risks is needed to make ideal treatment decisions.
 
JAMA INTERNAL MEDICINE
 
More than 18% of all lung cancers detected by LDCT in the NLST seem to be indolent, and overdiagnosis should be considered when describing the risks of LDCT screening for lung cancer.
In patients with stable CAD and objectively documented myocardial ischemia, PCI with MT was not associated with a reduction in death, nonfatal MI, unplanned revascularization, or angina compared with MT alone.
Duration of diabetes and advancing age independently predict diabetes morbidity and mortality rates. As long-term survivorship with diabetes increases and as the population ages, more research and public health efforts to reduce hypoglycemia will be needed to complement ongoing efforts to reduce cardiovascular and microvascular complications.
Differences in the sex-specific diagnostic performance of CPCs are small and do not seem to support the use of women-specific CPCs in the early diagnosis of AMI.
 
MEDICINA CLINICA
 
No existen protocolos claramente establecidos para el tratamiento de la boca seca. El objetivo de este trabajo es realizar una revisión sistemática de la literatura médica de los últimos 10 años. Hemos utilizado las palabras: «dry mouth», «prognosis», «treatment» y «dentistry». En una primera búsqueda hemos encontrado 1.450 entradas. Con la restricción «clinical trials OR randomized controlled trial OR systemic reviews» se han reducido a 522, de las que 145 eran metaanálisis y revisiones sistemáticas. Se han eliminado las que no eran pertinentes al tema y han quedado reducidas a 53. Posteriormente se descartaron 24 (8 no pertinentes, 7 revisiones y 9 opiniones personales). De los 29 artículos analizados, 15 son ensayos clínicos controlados, 2 ensayos no controlados, 4 estudios observacionales, 2 revisiones sistemáticas y 5 revisiones. Los enfermos mejor estudiados son los pacientes con síndrome de Sjögren y los pacientes irradiados. El tratamiento se centra en el etiológico, preventivo, sintomático, de estimulación salival local y sistémicos. Podemos concluir que el tratamiento debe ser individualizado, pudiéndose aplicar sustitutos salivales y diferentes técnicas de estimulación mecánica.
Las principales manifestaciones clínicas de la insuficiencia cardiaca (IC) se deben a la retención de fluidos, por lo que los tratamientos dirigidos a la mejoría de los síntomas congestivos tienen un papel central en su abordaje. Los diuréticos siguen siendo la piedra angular del tratamiento de la congestión, siendo prescritos en la mayoría de los pacientes con IC. A pesar de su uso extendido, existe escasa evidencia científica proveniente de estudios prospectivos y aleatorizados que sirva de guía para su utilización. Con el uso crónico de diuréticos y en estadios avanzados de IC, estos pueden dejar de ser eficaces en el control de la retención hidrosalina. En esta revisión se describen los mecanismos de acción de los principales diuréticos disponibles para el tratamiento de la IC, su utilidad clínica basada en la evidencia científica disponible y las estrategias para superar la resistencia a diuréticos.
El EAT-40, utilizando un punto de corte de 21, es un instrumento de cribado adecuado de casos de TCA en población española.
Los resultados contradicen la recomendación de aportar suplementos, no siendo una estrategia efectiva ni bien tolerada. Aunque podrían reducir el riesgo de caídas en valores muy bajos de vitamina D, los resultados son insatisfactorios cuando los mayores no presentan deficiencia de esta, debiéndose considerar la posibilidad de acontecimientos adversos.
 
REVISTA ESPAÑOLA DE CARDIOLOGIA
 
Se confirma una mortalidad significativamente menor entre los pacientes que presentan un incremento del índice de masa corporal y del perímetro de cintura. Los resultados muestran además que esta protección desaparece al alcanzar valores elevados.
La tabla SCORE calibrado identifica a más pacientes de alto riesgo que las del SCORE de bajo riesgo y el SCORE con colesterol unido a lipoproteínas de alta densidad, por lo que su utilización implicaría tratar a más pacientes con estatinas. Son necesarios estudios de validación del SCORE para valorar la tabla más adecuada en nuestro medio.
Conocer el impacto de la enfermedad coronaria en la sociedad a través de las medidas epidemiológicas básicas y su evolución es fundamental para evaluar la efectividad de los tratamientos y organizar la distribución de recursos. En la siguiente revisión narrativa, se presentan datos sobre prevalencia, incidencia y pronóstico de la enfermedad coronaria en general y del síndrome coronario agudo en particular.
 
THE LANCET
 
Millions of people will continue to be diagnosed with cancer every year for the foreseeable future. These patients all need access to optimum health care. Population-based cancer survival is a key measure of the overall effectiveness of health systems in management of cancer. Survival varies very widely around the world. Global surveillance of cancer survival is needed, because unless these avoidable inequalities are measured, and reported on regularly, nothing will be done explicitly to reduce them.
Cancer is a global and growing, but not uniform, problem. An increasing proportion of the burden is falling on low-income and middle-income countries because of not only demographic change but also a transition in risk factors, whereby the consequences of the globalisation of economies and behaviours are adding to an existing burden of cancers of infectious origin. We argue that primary prevention is a particularly effective way to fight cancer, with between a third and a half of cancers being preventable on the basis of present knowledge of risk factors. Primary prevention has several advantages: the effectiveness could have benefits for people other than those directly targeted, avoidance of exposure to carcinogenic agents is likely to prevent other non-communicable diseases, and the cause could be removed or reduced in the long term--eg, through regulatory measures against occupational or environmental exposures (ie, the preventive effort does not need to be renewed with every generation, which is especially important when resources are in short supply). Primary prevention must therefore be prioritised as an integral part of global cancer control.
Greece's economic crisis has deepened since it was bailed out by the international community in 2010. The country underwent the sixth consecutive year of economic contraction in 2013, with its economy shrinking by 20% between 2008 and 2012, and anaemic or no growth projected for 2014. Unemployment has more than tripled, from 7·7% in 2008 to 24·3% in 2012, and long-term unemployment reached 14·4%. We review the background to the crisis, assess how austerity measures have affected the health of the Greek population and their access to public health services, and examine the political response to the mounting evidence of a Greek public health tragedy.
HPV-based screening provides 60-70% greater protection against invasive cervical carcinomas compared with cytology. Data of large-scale randomised trials support initiation of HPV-based screening from age 30 years and extension of screening intervals to at least 5 years.
Changes in blood pressure after RDN persist long term in patients with treatment-resistant hypertension, with good safety.
Some 40 years ago a metaphor was posed that cancer was such an insidious adversary that a declaration of war on the disease was justified. Although this statement was a useful inspiration for enlistment of resources, despite extraordinary progress in our understanding of disease pathogenesis, in most cases and for most forms of cancer this war has not been won. A second metaphor was about magic bullets--targeted therapies based on knowledge of mechanisms that were envisaged to strike with devastating consequences for the disease. The reality, however, is that targeted therapies are generally not curative or even enduringly effective, because of the adaptive and evasive resistance strategies developed by cancers under attack. In this Series paper, I suggest that, much like in modern warfare, the war on cancer needs to have a battlespace vision.
Pimavanserin may benefit patients with Parkinson's disease psychosis for whom few other treatment options exist. The trial design used in this study to manage placebo response could have applicability to other studies in neuropsychiatric disease.
 
THE NEW ENGLAND JOURNAL OF MEDICINE
 
More than 40 medical specialties have identified "Choosing Wisely" lists of five overused or low-value services. But these services vary widely in potential impact on care and spending, and specialty societies often name other specialties' services as low value.
Pregabalin provided significantly improved treatment outcomes as compared with placebo, and augmentation rates were significantly lower with pregabalin than with 0.5 mg of pramipexole. (Funded by Pfizer; ClinicalTrials.gov number, NCT00806026.).
In a general obstetrical population, prenatal testing with the use of cfDNA had significantly lower false positive rates and higher positive predictive values for detection of trisomies 21 and 18 than standard screening. (Funded by Illumina; ClinicalTrials.gov number, NCT01663350.).
Occupational asthma has been defined as asthma due to conditions attributable to work exposures, not to causes outside the workplace. This review focuses on current data on pathogenesis, evaluation, and management.
 
THORAX
 
The combination of budesonide and formoterol on demand improves asthma control by reducing EIB in the same order of magnitude as regular budesonide treatment despite a substantially lower total steroid dose. Both these treatments were superior to terbutaline on demand, which did not alter the bronchial response to exercise. The results question the recommendation of prescribing SABAs as the only treatment for EIB in mild asthma.
 
 

                      

 

1as JART SAMFyC 2017

 


____________________________

 Para pacientes
@pontealdiaAP
 @pontealdiaURG
55 e.SAMFyC

 


 

semFYC
 

 

Estadisticas

Ver contenido por hits : 1016728



La SAMFyC:
 C/ Arriola, 4, bajo D, CP.18001 - Granada. Email: samfyc@samfyc.es; Teléfono: 958 804 201 - Fax: 958 804 202. Horario de invierno: lunes a jueves de 9:00 a 17:30 horas; viernes de 9:00 a 14:30 horas. Horario de verano: lunes a viernes de 8:00 a 15:00h. Todos los derechos reservados. Aviso Legal. 


¡CSS Válido!

Diseño web